Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Animals (1)
- Beta Catenin (1)
- CAPTEM (1)
- Caco-2 Cells (1)
- Cancer (1)
-
- Cancer prevention (1)
- Capecitabine (1)
- Cell Line (1)
- Cell Line, Tumor (1)
- Cell Nucleus (1)
- Cell Proliferation (1)
- Cell signalling (1)
- Chemotherapy (1)
- Colitis (1)
- Colorectal Neoplasms (1)
- Gastroenteropancreatic (1)
- HCT116 Cells (1)
- HT29 Cells (1)
- Humans (1)
- Intestinal stem cells (1)
- Mice (1)
- Molecular Weight (1)
- Mutation (1)
- Neoplasm Transplantation (1)
- Neuroendocrine tumor (1)
- Proteasome Endopeptidase Complex (1)
- Stem-cell research (1)
- Temozolomide (1)
- Transcription Factor 4 (1)
- Transcriptional Activation (1)
Articles 1 - 2 of 2
Full-Text Articles in Gastroenterology
Capecitabine And Temozolomide In Neuroendocrine Tumor Of Unknown Primary, Aman Chauhan, Zainab Farooqui, Leaundra Murray, Heidi L. Weiss, Zin W. Myint, Arun Kumar A. Raajasekar, B. Mark Evers, Susanne M. Arnold, Lowell B. Anthony
Capecitabine And Temozolomide In Neuroendocrine Tumor Of Unknown Primary, Aman Chauhan, Zainab Farooqui, Leaundra Murray, Heidi L. Weiss, Zin W. Myint, Arun Kumar A. Raajasekar, B. Mark Evers, Susanne M. Arnold, Lowell B. Anthony
Internal Medicine Faculty Publications
Incidence of low grade well-differentiated neuroendocrine tumors (NET) is on the rise. The North American Neuroendocrine Tumor Society estimates that the United States has more than 150,000 gastroenteropancreatic NET patients. About 10% of metastatic NETs can be unknown primary, and due to their rarity, dedicated treatment algorithms and regimens are not defined. Combination of capecitabine and temozolomide (CAPTEM) is one of the systemic treatments used in gastroenteropancreatic NETs. We explored clinical activity of CAPTEM in NET of unknown primary. Methods. Retrospective review of NET of unknown primary managed at the University of Kentucky over the past five years (2012–2016). …
Beta-Catenin Cleavage Enhances Transcriptional Activation, Tatiana Goretsky, Emily M. Bradford, Qing Ye, Olivia F. Lamping, Tomas Vanagunas, Mary Pat Moyer, Patrick C. Keller, Preetika Sinh, Josep M. Llovet, Tianyan Gao, Qing-Bai She, Linheng Li, Terrence A. Barrett
Beta-Catenin Cleavage Enhances Transcriptional Activation, Tatiana Goretsky, Emily M. Bradford, Qing Ye, Olivia F. Lamping, Tomas Vanagunas, Mary Pat Moyer, Patrick C. Keller, Preetika Sinh, Josep M. Llovet, Tianyan Gao, Qing-Bai She, Linheng Li, Terrence A. Barrett
Internal Medicine Faculty Publications
Nuclear activation of Wnt/β-catenin signaling is required for cell proliferation in inflammation and cancer. Studies from our group indicate that β-catenin activation in colitis and colorectal cancer (CRC) correlates with increased nuclear levels of β-catenin phosphorylated at serine 552 (pβ-Cat552). Biochemical analysis of nuclear extracts from cancer biopsies revealed the existence of low molecular weight (LMW) pβ-Cat552, increased to the exclusion of full size (FS) forms of β-catenin. LMW β-catenin lacks both termini, leaving residues in the armadillo repeat intact. Further experiments showed that TCF4 predominantly binds LMW pβ-Cat552 in the nucleus of inflamed and …